The results support the development of CB2 receptor and GPR55 inhibitors (i.e., antagonists, inverse-agonists, negative allosteric modulators), but also suggest that development of enzyme enhancers (enzyme potentiators) of ABHD6, MAGL, FAAH enzymes, and possibly their combination with or without a CB2 receptor inhibitor and a GPR55 inhibitor will provide alternative approaches to treat patients with TS that are diagnosed with increased 2-AG level. The gene discussed is MGLL; the disease is Timothy syndrome.